Institute for International Research

Best Rates Now Available

Register by January 29th and Save $300 off the Standard Rates

Keynote Presentations

Gregory L. Verdine, Ph.D.
Erving Professor of Chemistry
Harvard University

John Maraganore, Ph.D.
Chief Executive Officer
Alnylam Pharmaceuticals, Inc.

Claes R. Wahlestedt, M.D., Ph.D.
Professor, Director of Neuroscience Discovery
The Scripps Research Institute - Florida

Scientific Advisory Committee

David Brown, Ph.D., Director of Discovery, Mirna Therapeutics

Masad Damha, Ph.D., James McGill Professor of Chemistry, McGill University

Satya Kuchimanchi, Ph.D., Associate Director, RNAi Lead Development, Alnylam

Dmitry Samarsky, Ph.D., VP, Technology Development, RXi Pharmaceuticals

THE conference for comparing strategies and advances for different oligonucleotide subclasses and what it will take to discover the next generation of drugs. This is your chance to gain vital insights into:

• Preclinical chemical modification strategies to improve drug-like properties
• How to overcome cellular barriers to siRNA delivery
• How to choose the right safety assessment strategy for different oligo subclasses
• Preclinical and clinical experiences from 13 case studies
• Creative techniques for oligonucleotide lead discovery and candidate selection

Featured sessions and compelling data include:

• Understanding rules for nanoparticle-mediated delivery of siRNA: What are we learning?
• Combinatorial development of synthetic siRNA delivery systems
• Profiling of conformationally constrained nucleosides for use in antisense oligonucleotides
• Combination of oligo configuration and chemical modification provides drug-like properties to RNAi molecules
• Chemical modifications and their impact on aptamers
• Case study on first efficacy and clinical safety results from systemic delivery of a splice switching PMO
• Case study of Phase 1 and 2 results of OGX-011 for prostate cancer
• Preclinical and Phase 1 results of L-aptamers NOX-E36 and NOX-A12

IBC's 2nd annual Oligonucleotide Therapeutics Discovery conference, to be held alongside TIDES® 2010, will provide you with creative discovery, preclinical and early clinical approaches to accelerate lead generation, improve drug-like properties and select the best oligonucleotide candidates for development. Novel strategies and preclinical and clinical case studies will be included for many oligonucleotide classes - from siRNA, miRNA, antisense, aptamers, and more - allowing you to compare the advantages and challenges of multiple platforms at one conference. Designed for discovery, preclinical and early development scientists, this conference will also offer a big pharma viewpoint on what they feel is still necessary to translate the potential of oligonucleotides into new therapies. 3-day pass registrants for Oligonucleotide Therapeutics Discovery will also gain access to all concurrent TIDES® sessions.

IBC's annual TIDES® conference continues to be THE place to meet all the important players in oligonucleotide and peptide therapeutics and diagnostic development and manufacturing, as well as raw material and equipment supply - and now discovery too. » Review the TIDES® agenda.